Ahead of biosimilar competition to Humira (adalimumab) kicking off in the US, Organon CEO Kevin Ali has made a bold prediction about the extent to which prices could eventually be slashed for rivals to the top-selling biologic blockbuster.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?